MA56183A - Pyrazolo-pyridines hétéroaromatiques substituées et leur utilisation en tant que modulateurs du récepteur glun2b - Google Patents

Pyrazolo-pyridines hétéroaromatiques substituées et leur utilisation en tant que modulateurs du récepteur glun2b

Info

Publication number
MA56183A
MA56183A MA056183A MA56183A MA56183A MA 56183 A MA56183 A MA 56183A MA 056183 A MA056183 A MA 056183A MA 56183 A MA56183 A MA 56183A MA 56183 A MA56183 A MA 56183A
Authority
MA
Morocco
Prior art keywords
pyrazolo
pyridines
receptor modulators
substituted heteroaromatic
glun2b receptor
Prior art date
Application number
MA056183A
Other languages
English (en)
Inventor
Christa Chrovian
Curt Dvorak
Christine Gelin
Afton Hiscox
Michael A Letavic
Andrew Samant
Brice Stenne
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA56183A publication Critical patent/MA56183A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA056183A 2019-06-14 2020-06-12 Pyrazolo-pyridines hétéroaromatiques substituées et leur utilisation en tant que modulateurs du récepteur glun2b MA56183A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962861665P 2019-06-14 2019-06-14
PK34920 2020-06-03

Publications (1)

Publication Number Publication Date
MA56183A true MA56183A (fr) 2022-04-20

Family

ID=73781827

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056183A MA56183A (fr) 2019-06-14 2020-06-12 Pyrazolo-pyridines hétéroaromatiques substituées et leur utilisation en tant que modulateurs du récepteur glun2b

Country Status (21)

Country Link
US (2) US11530210B2 (fr)
EP (1) EP3982958A1 (fr)
JP (1) JP2022536424A (fr)
KR (1) KR20220024512A (fr)
CN (1) CN114007610A (fr)
AU (1) AU2020291188A1 (fr)
BR (1) BR112021025141A2 (fr)
CA (1) CA3143276A1 (fr)
CL (1) CL2021003257A1 (fr)
CO (1) CO2021016860A2 (fr)
CR (1) CR20210615A (fr)
DO (1) DOP2021000250A (fr)
EC (1) ECSP21090450A (fr)
IL (1) IL288858A (fr)
JO (1) JOP20210330A1 (fr)
MA (1) MA56183A (fr)
MX (1) MX2021015503A (fr)
PE (1) PE20220806A1 (fr)
SG (1) SG11202112405VA (fr)
TW (1) TW202115054A (fr)
WO (1) WO2020249785A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
US11447503B2 (en) 2019-06-14 2022-09-20 Janssen Pharmaceutica Nv Pyridine carbamates and their use as GLUN2B receptor modulators
CN113993583A (zh) 2019-06-14 2022-01-28 詹森药业有限公司 取代的吡唑并[4,3-b]吡啶及其作为GLUN2B受体调节剂的用途
BR112021025141A2 (pt) * 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b
KR20220024403A (ko) 2019-06-14 2022-03-03 얀센 파마슈티카 엔.브이. 치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도
US11459336B2 (en) 2019-06-14 2022-10-04 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as GluN2B receptor modulators
PH12021552839A1 (en) 2019-06-14 2022-10-03 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
EP3983075A1 (fr) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Pyrazolo-pyridine amides substitués et leur utilisation en tant que modulateurs du récepteur glun2b
CN114149425A (zh) * 2021-11-16 2022-03-08 上海应用技术大学 5-氟甲基吡啶衍生物和18-f同位素标记的5-氟甲基吡啶衍生物及其制备与应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407447D0 (en) 1994-04-14 1994-06-08 Glaxo Group Ltd Chemical compounds
CA2262502C (fr) 1996-07-31 2002-11-26 Nikken Chemicals Co., Ltd. Derives de 6-phenyltetrahydro-1,3-oxazine-2-one et compositions medicinales a base de ces composes
WO2002000629A1 (fr) 2000-06-26 2002-01-03 Merck & Co., Inc. Antagonistes des recepteurs nmda nr2b de l'iminopyrimidine
US6610723B2 (en) 2001-01-29 2003-08-26 Hoffmann-La Roche Inc. Imidazole derivatives
CA2452260C (fr) 2001-07-24 2011-09-06 Genset S.A. Nouveaux variants et exons du transporteur glyt1
KR20040111445A (ko) 2002-03-28 2004-12-31 에자이 가부시키가이샤 신경퇴행성 질환 치료용 ｃ─Ｊｕｎ Ｎ─말단 키나아제억제제로서의 ７─아자인돌
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
EP1720860A1 (fr) 2004-02-18 2006-11-15 AstraZeneca AB Composes de triazole et leur utilisation en tant qu'antagonistes du recepteur metabotrope du glutamate
AU2005286593A1 (en) 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyridine compounds, process for their preparation and compositions containing them
US7807704B2 (en) 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
NZ581127A (en) 2007-05-25 2012-06-29 Abbott Gmbh & Co Kg Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
WO2009004430A1 (fr) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones et composés hétérocycliques apparentés comme potentialisateurs de récepteurs du glutamate
US20100227846A1 (en) 2007-08-30 2010-09-09 Takeda Pharmaceutical Company Limited Substituted pyrazole derivative
US20100249164A1 (en) 2007-10-31 2010-09-30 Renger John J Modulation of sleep with nr2b receptor antagonists
NZ588698A (en) 2008-03-27 2012-06-29 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
WO2009157196A1 (fr) 2008-06-25 2009-12-30 武田薬品工業株式会社 Composé amide
BRPI0917540A2 (pt) 2008-08-05 2015-11-17 Daiichi Sankyo Co Ltd composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
CA2738849C (fr) 2008-10-16 2016-06-28 Addex Pharma S.A. Derives d'indole et de benzomorpholine en tant que modulateurs des recepteurs metabotropiques du glutamate
KR101048448B1 (ko) * 2008-11-21 2011-07-11 한국화학연구원 신규 피라졸로[4,3-ｂ]피리딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
CN102264743B (zh) 2008-11-25 2015-02-11 罗彻斯特大学 Mlk抑制剂及其使用方法
WO2010108187A2 (fr) 2009-03-20 2010-09-23 Brandeis University Composés et procédés pour traiter les infections microbiennes gastro-intestinales mammaliennes
US8906914B2 (en) 2009-08-18 2014-12-09 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid hydrolase
US8765784B2 (en) 2010-06-09 2014-07-01 Merck Sharp & Dohme Corp. Positive allosteric modulators of MGLUR2
JP5990106B2 (ja) 2011-01-28 2016-09-07 佐藤製薬株式会社 縮環化合物
JP2012188363A (ja) 2011-03-09 2012-10-04 Dainippon Sumitomo Pharma Co Ltd アザベンゾイミダゾロン誘導体
EP2570415B1 (fr) 2011-09-19 2015-08-26 Sanofi N-[4-(1H-Pyrazolo[3,4-b]pyrazin-6-yl)-phényl]-sulfonamides et leur utilisation en tant que produits pharmaceutiques
WO2013060029A1 (fr) 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp Modulateurs allostériques des récepteurs métabotropiques du glutamate
US9434743B2 (en) 2012-03-02 2016-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
WO2014124651A1 (fr) 2013-02-15 2014-08-21 Københavns Universitet Dérivés de pyrrolidine-2-acide carboxylique utilisés en tant qu'antagonistes de iglur
EP2970200A1 (fr) 2013-03-13 2016-01-20 Abbvie Inc. Inhibiteurs de pyridine cdk9 kinase
JP6325078B2 (ja) 2013-03-15 2018-05-16 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． ヘテロ環式化合物およびその使用
SG11201510409QA (en) 2013-06-21 2016-01-28 Zenith Epigenetics Corp Novel bicyclic bromodomain inhibitors
PT3049417T (pt) 2013-07-31 2019-01-24 Merck Patent Gmbh Piridinas, pirimidinas e pirazinas, como inibidores de btk e utilizações das mesmas
PT3180329T (pt) 2014-08-15 2020-06-08 Janssen Pharmaceuticals Inc Triazóis como inibidores do recetor nr2b
HUE049278T2 (hu) 2014-08-15 2020-09-28 Janssen Pharmaceuticals Inc Pirazolok
WO2016081649A1 (fr) 2014-11-18 2016-05-26 Emory University Dérivés de thiéno[2,3-d]pyrimidin-4-one utilisés comme modulateurs de nmdar et leurs utilisations associées
MA41803A (fr) 2015-03-24 2018-01-30 Almirall Sa Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques
BR112017023038A2 (pt) * 2015-04-29 2018-07-03 Janssen Pharmaceutica Nv imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa
LT3319963T (lt) * 2015-07-09 2020-03-25 Janssen Pharmaceutica Nv Pakeistieji 4-azaindolai ir jų, kaip glun2b receptoriaus moduliatorių, panaudojimas
CA3014314A1 (fr) 2016-02-10 2017-08-17 Janssen Pharmaceutica Nv 1,2,3-triazoles substitues utilises comme modulateurs de nmda selectifs de nr2b
TW201819376A (zh) * 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
US11447503B2 (en) 2019-06-14 2022-09-20 Janssen Pharmaceutica Nv Pyridine carbamates and their use as GLUN2B receptor modulators
IL271149B2 (en) 2017-06-14 2024-05-01 Trevena Inc Compounds for modulating s1p1 activity and methods of using the same
US10766893B2 (en) 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
WO2019193516A2 (fr) 2018-04-04 2019-10-10 Janssen Pharmaceutica Nv Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b
CN110294756A (zh) 2019-06-04 2019-10-01 广州市原子高科同位素医药有限公司 GluN2B亚基靶向型中枢神经系统正电子示踪剂及其制备
KR20220024403A (ko) 2019-06-14 2022-03-03 얀센 파마슈티카 엔.브이. 치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도
BR112021025141A2 (pt) * 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b
US11459336B2 (en) 2019-06-14 2022-10-04 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as GluN2B receptor modulators
CN113993583A (zh) 2019-06-14 2022-01-28 詹森药业有限公司 取代的吡唑并[4,3-b]吡啶及其作为GLUN2B受体调节剂的用途
EP3983075A1 (fr) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Pyrazolo-pyridine amides substitués et leur utilisation en tant que modulateurs du récepteur glun2b

Also Published As

Publication number Publication date
AU2020291188A1 (en) 2022-01-20
US11530210B2 (en) 2022-12-20
BR112021025141A2 (pt) 2022-01-25
SG11202112405VA (en) 2021-12-30
TW202115054A (zh) 2021-04-16
US20230045960A1 (en) 2023-02-16
US20210017169A1 (en) 2021-01-21
IL288858A (en) 2022-02-01
PE20220806A1 (es) 2022-05-20
MX2021015503A (es) 2022-04-20
JP2022536424A (ja) 2022-08-16
CA3143276A1 (fr) 2020-12-17
WO2020249785A1 (fr) 2020-12-17
CN114007610A (zh) 2022-02-01
DOP2021000250A (es) 2022-03-31
CL2021003257A1 (es) 2022-08-19
JOP20210330A1 (ar) 2023-01-30
EP3982958A1 (fr) 2022-04-20
CO2021016860A2 (es) 2022-01-17
CR20210615A (es) 2022-01-31
ECSP21090450A (es) 2022-01-31
KR20220024512A (ko) 2022-03-03

Similar Documents

Publication Publication Date Title
MA56183A (fr) Pyrazolo-pyridines hétéroaromatiques substituées et leur utilisation en tant que modulateurs du récepteur glun2b
MA52244A (fr) Pyridine et pyrimidines substituées et leur utilisation en tant que modulateurs du récepteur glun2b
MA56196A (fr) Pyrazolo-pyridine amides substitués et leur utilisation en tant que modulateurs du récepteur glun2b
EP3861130A4 (fr) Modulateurs génétiques modifiés
DK3743406T3 (da) Tmem16a modulatorer
IL287379A (en) Modulators of the integrated stress response pathway
MA44225A (fr) Sulfonylurées et composés apparentés et leur utilisation
MA51224A (fr) Composés de sulfonamide et leur utilisation
HUE059242T2 (hu) Azetidin-származékok mint kemokin receptor modulátorok és felhasználásuk
DK3490986T3 (da) Piperidin-cxcr7-receptormodulatorer
MA52284A (fr) Anticorps anti-hla-g et leur utilisation
MA45709A (fr) Composés diazahétérobicycliques substitués et leur utilisation
IL281492A (en) Modulators of pnpla3 expression
EP3899024A4 (fr) Modulateurs de l'expression de hsd17b13
HUE047460T2 (hu) Szubsztituált 4-azaindolok és ezek alkalmazása mint GLUN2B receptor modulátorok
EP3527597A4 (fr) Composition polymérisable pour matériau optique et son utilisation
EP3580223A4 (fr) Modulateurs du récepteur des strogènes de benzothiophène
EP3746447C0 (fr) Modulateurs spiro-lactames des récepteurs nmda et leurs utilation
EP3675849A4 (fr) Modulateurs de tétrahydrocannabinol
EP3490994C0 (fr) Modulateurs spiro-lactames et bis-spiro-lactames des récepteurs nmda et leurs utilisations
MA50440A (fr) Imidazopyridinamides substituées et leur utilisation
EP3758704A4 (fr) Modulateurs de l'expression d'irf4
EP3558318A4 (fr) Modulateurs des récepteurs nmda et utilisations de ceux-ci
HUE047761T2 (hu) Ösztrogén receptor modulátorok
EP3931328A4 (fr) Modulateurs de l'expression de malat1